Bayer execs calm about compulsory licensing clauses
By Wang Xin | China Daily | Updated: 2010-11-24 07:57
|
Display promoting Bayer's iconic over-the-counter aspirin. The company will invest about $4.2 billion in research this year. Provided to China Daily |
Clauses in the latest revision of China's patent law permitting compulsory licensing of patented medicines has triggered concern among some companies, but pharmaceutical and chemical giant Bayer is remaining calm.
Photo
